Novartis' oral BTK drug moves the needle in CINDU Novartis is set to expand the label for its oral BTK inhibitor Rhapsido, keeping the drug on course to become one of its biggest-ever brands.

#Novartis is on course to expand the label for its recently approved #oralBTKinhibitor Rhapsido, after chalking up a win in chronic #skindisorder chronic inducible urticaria (#CINDU).

pharmaphorum.com/news/novarti...

Data builds on Roche's dominance in primary progressive MS Roche looks on track to add oral BTK inhibitor fenebrutinib to treatment options for primary progressive multiple sclerosis.

#Roche #primaryprogressiveMS #MS #phase3trial #oralBTKinhibitor #fenebrutinib #primaryprogressivemultiplesclerosis #PPMS #Ocrevus #ocrelizumab #FENtrepidtrial #disabilityprogression #CD20targetingantibody #FENhance1trial #FENhance2trial #clinicalbenefit #diseasemodifyingtherapy
zurl.co/MGaVR

Data builds on Roche's dominance in primary progressive MS Roche looks on track to add oral BTK inhibitor fenebrutinib to treatment options for primary progressive multiple sclerosis.

#Roche has revealed the data behind a positive phase 3 trial for its #oralBTKinhibitor fenebrutinib in primary progressive #multiplesclerosis (PPMS), revealing that it was at least as effective as its blockbuster Ocrevus administered intravenously.